RT Journal Article SR Electronic T1 Aging-related cell type-specific pathophysiologic immune responses that exacerbate disease severity in aged COVID-19 patients JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.09.13.21263504 DO 10.1101/2021.09.13.21263504 A1 Yuan Hou A1 Yadi Zhou A1 Michaela U. Gack A1 Yuan Luo A1 Lara Jehi A1 Timothy Chan A1 Haiyuan Yu A1 Charis Eng A1 Andrew A. Pieper A1 Feixiong Cheng YR 2021 UL http://medrxiv.org/content/early/2021/09/16/2021.09.13.21263504.abstract AB Coronavirus Disease 2019 (COVID-19) is especially severe in aged patients, defined as 65 years or older, for reasons that are currently unknown. To investigate the underlying basis for this vulnerability, we performed multimodal data analyses on immunity, inflammation, and COVID-19 incidence and severity as a function of age. Our analysis leveraged age-specific COVID-19 mortality and laboratory testing from a large COVID-19 registry, along with epidemiological data of ∼3.4 million individuals, large-scale deep immune cell profiling data, and single-cell RNA-sequencing data from aged COVID-19 patients across diverse populations. To begin, we confirmed a significantly increased rate of severe outcomes in aged COVID-19 patients. Furthermore, we identified increased inflammatory markers (C-reactive protein, D-dimer, and neutrophil-lymphocyte ratio), viral entry factors in secretory cells, and TGFβ-mediated immune-epithelial cell interactions, as well as reduction in both naïve CD8 T cells and expression of interferon antiviral defense genes (i.e., IFITM3 and TRIM22), along with strong TGF-beta mediated immune-epithelial cell interactions (i.e., secretory - T regulatory cells), in aged severe COVID-19 patients. Taken together, our findings point to immuno-inflammatory factors that could be targeted therapeutically to reduce morbidity and mortality in aged COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institute of Aging (R01AG066707 and 3R01AG066707-01S1) and the National Heart, Lung, and Blood Institute (R00HL138272) to F.C. This work has also been supported by the National Institute of Neurological Disorders and Stroke (3R01NS097719-04S1) to F.C. and L.J. This work has also been supported in part by the VeloSano Pilot Program (Cleveland Clinic Taussig Cancer Institute) to F.C.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:n/aAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe clinical and transcriptomic datasets used in this study are public available, the details see Supplementary Table 1. The code for single cell analysis can be found in https://github.com/ChengF-Lab/COVID-19_Map. https://github.com/ChengF-Lab/COVID-19_Map